Non-viral gene therapy for bone tissue engineering

Fiona Wegman; F. Cumhur Öner; Wouter J.A. Dhert; Jacqueline Alblas

doi:10.1080/02648725.2013.801227

Non-viral gene therapy for bone tissue engineering

Fiona Wegman, F. Cumhur Öner, Wouter J.A. Dhert, Jacqueline Alblas^*

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

18 Citations (Scopus)

Abstract

The possibilities of using gene therapy for bone regeneration have been extensively investigated. Improvements in the design of new transfection agents, combining vectors and delivery/release systems to diminish cytotoxicity and increase transfection efficiencies have led to several successful in vitro, ex vivo and in vivo strategies. These include growth factor or short interfering ribonucleic acid (siRNA) delivery, or even enzyme replacement therapies, and have led to increased osteogenic differentiation and bone formation in vivo. These results provide optimism to consider use in humans with some of these gene-delivery strategies in the near future.

Original language	English
Pages (from-to)	206-220
Number of pages	15
Journal	Biotechnology and Genetic Engineering Reviews
Volume	29
Issue number	2
DOIs	https://doi.org/10.1080/02648725.2013.801227
Publication status	Published - 1 Oct 2013

Keywords

Bone
Gene activated matrix
Gene therapy
Multipotent stromal cell (MSC)
Non-viral
Osteogenicity

Access to Document

10.1080/02648725.2013.801227

Cite this

@article{569d3846ac2343b091a218f09ab43440,

title = "Non-viral gene therapy for bone tissue engineering",

abstract = "The possibilities of using gene therapy for bone regeneration have been extensively investigated. Improvements in the design of new transfection agents, combining vectors and delivery/release systems to diminish cytotoxicity and increase transfection efficiencies have led to several successful in vitro, ex vivo and in vivo strategies. These include growth factor or short interfering ribonucleic acid (siRNA) delivery, or even enzyme replacement therapies, and have led to increased osteogenic differentiation and bone formation in vivo. These results provide optimism to consider use in humans with some of these gene-delivery strategies in the near future.",

keywords = "Bone, Gene activated matrix, Gene therapy, Multipotent stromal cell (MSC), Non-viral, Osteogenicity",

author = "Fiona Wegman and \{Cumhur {\"O}ner\}, F. and Dhert, \{Wouter J.A.\} and Jacqueline Alblas",

year = "2013",

month = oct,

day = "1",

doi = "10.1080/02648725.2013.801227",

language = "English",

volume = "29",

pages = "206--220",

journal = "Biotechnology and Genetic Engineering Reviews",

issn = "0264-8725",

publisher = "Taylor and Francis Ltd.",

number = "2",

}

TY - JOUR

T1 - Non-viral gene therapy for bone tissue engineering

AU - Wegman, Fiona

AU - Cumhur Öner, F.

AU - Dhert, Wouter J.A.

AU - Alblas, Jacqueline

PY - 2013/10/1

Y1 - 2013/10/1

N2 - The possibilities of using gene therapy for bone regeneration have been extensively investigated. Improvements in the design of new transfection agents, combining vectors and delivery/release systems to diminish cytotoxicity and increase transfection efficiencies have led to several successful in vitro, ex vivo and in vivo strategies. These include growth factor or short interfering ribonucleic acid (siRNA) delivery, or even enzyme replacement therapies, and have led to increased osteogenic differentiation and bone formation in vivo. These results provide optimism to consider use in humans with some of these gene-delivery strategies in the near future.

AB - The possibilities of using gene therapy for bone regeneration have been extensively investigated. Improvements in the design of new transfection agents, combining vectors and delivery/release systems to diminish cytotoxicity and increase transfection efficiencies have led to several successful in vitro, ex vivo and in vivo strategies. These include growth factor or short interfering ribonucleic acid (siRNA) delivery, or even enzyme replacement therapies, and have led to increased osteogenic differentiation and bone formation in vivo. These results provide optimism to consider use in humans with some of these gene-delivery strategies in the near future.

KW - Bone

KW - Gene activated matrix

KW - Gene therapy

KW - Multipotent stromal cell (MSC)

KW - Non-viral

KW - Osteogenicity

UR - https://www.scopus.com/pages/publications/84887490741

U2 - 10.1080/02648725.2013.801227

DO - 10.1080/02648725.2013.801227

M3 - Article

C2 - 24568281

AN - SCOPUS:84887490741

SN - 0264-8725

VL - 29

SP - 206

EP - 220

JO - Biotechnology and Genetic Engineering Reviews

JF - Biotechnology and Genetic Engineering Reviews

IS - 2

ER -

Non-viral gene therapy for bone tissue engineering

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this